Home › Heart Failure › NCT07403669

Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment

Cardiovascular Kidney and Metaboolic (CKM) Health Assessment and Patient Empowerment in chROnic Disease Using a Health Coach INtervention ModEl: A Randomized Clinical Trial

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Men and women over 18 years of age are included
* Eligible subjects must have one of the risk factor/ disease component of CKM:
* Diabetes with A1C of 7.5 or higher;
* or Heart disease with stent placement;
* or Coronary Artery Bypass Graft (CABG) in the last 12 months;
* or Chronic Kidney Disease (CKD) stage 2- 4
* and, in those with Heart failure, a recent hospitalization within one week of enrollment is required

Exclusion Criteria:

* Those subjects who are not willing to sign an informed consent

About the study

The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and vital sign monitoring device in reducing CKM disease burden using an algorithm obtained from biomarkers and diagnostics utilizing remote sensor driven technology tools, care coordination and patient empowerment.

What is being tested

• CHAPERONE AI (other)
• CKMiq AI (device)
• Quality of Life (other)

Sponsor: Aventyn, Inc. · Participants: 300 · Started: Oct 22, 2025

Contact the study team

• Navin Govind Steering Committtee, MS · Phone: 2317942328
• Aditya Vijay, MS · Phone: 2317942328

Official record on ClinicalTrials.gov — NCT07403669

Locations in the U.S.

Conditions

• Heart Failure
• Diabetes
• Kidney Diseases

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.